Document detail
ID

oai:arXiv.org:2408.08193

Topic
Computer Science - Human-Computer ...
Author
Gualano, Ria J. Jiang, Lucy Zhang, Kexin Shende, Tanisha Won, Andrea Stevenson Azenkot, Shiri
Category

Computer Science

Year

2024

listing date

8/21/2024

Keywords
embodied people disabilities vr
Metrics

Abstract

With the increasing adoption of social virtual reality (VR), it is critical to design inclusive avatars.

While researchers have investigated how and why blind and d/Deaf people wish to disclose their disabilities in VR, little is known about the preferences of many others with invisible disabilities (e.g., ADHD, dyslexia, chronic conditions).

We filled this gap by interviewing 15 participants, each with one to three invisible disabilities, who represented 22 different invisible disabilities in total.

We found that invisibly disabled people approached avatar-based disclosure through contextualized considerations informed by their prior experiences.

For example, some wished to use VR's embodied affordances, such as facial expressions and body language, to dynamically represent their energy level or willingness to engage with others, while others preferred not to disclose their disability identity in any context.

We define a binary framework for embodied invisible disability expression (public and private) and discuss three disclosure patterns (Activists, Non-Disclosers, and Situational Disclosers) to inform the design of future inclusive VR experiences.

;Comment: To appear at ASSETS 2024

Gualano, Ria J.,Jiang, Lucy,Zhang, Kexin,Shende, Tanisha,Won, Andrea Stevenson,Azenkot, Shiri, 2024, "I Try to Represent Myself as I Am": Self-Presentation Preferences of People with Invisible Disabilities through Embodied Social VR Avatars

Document

Open

Share

Source

Articles recommended by ES/IODE AI

Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
gravis myasthenia study clinical phase baseline improvement mg-adl 340 week trial placebo period mg maintenance qw